Certis Oncology Solutions provides pre-clinical oncology research using Patient-Derived Orthotopic Xenograft (PDOX) mouse models. They establish PDOX models through microsurgery from patient tumor samples and test various drug therapies simultaneously in mice to provide treatment data to oncologists. Their PDOX models metastasize reliably and have a high tumor establishment success rate, providing more accurate pre-clinical data than traditional PDX models. Certis is expanding their tumor bank and testing facilities while publishing numerous studies showing PDOX models closely match patient tumor responses to therapies.
Certis Oncology | Pre-Clinical Research OfferingsArthurHolmes2
Certis Oncology Solutions provides pre-clinical oncology research services using Patient-Derived Orthotopic Xenograft (PDOX) mouse models. They have expanded their facilities and tumor bank. PDOX models more accurately reflect human cancer compared to traditional PDX models by implanting tumors in their original sites. Certis has affiliations with physicians to obtain tumors and drug response data. They have established over 300 PDOX models representing various cancer types. Certis offers drug screening and individualized treatment data to support cancer research and drug development. They have published several studies demonstrating the clinical relevance and predictive power of their PDOX models.
Certis OncologySolutions provides pre-clinical cancer research services using a technique called Patient-Derived Orthotopic Xenograft (PDOX) mouse modeling. They have an expanding tumor bank with over 300 patient tumors and drug response data. Their facilities include a 7,000 square foot facility in San Diego with lab space. Their unique PDOX model implants patient tumor samples into mice in the same anatomical site as the original tumor to provide a more clinically relevant model for testing drug therapies. Recent studies have shown their PDOX models accurately mimic patient responses to therapies. They offer guidance on pre-clinical studies, execution of drug screening, and publishing assistance to support cancer research.
Certis Oncology Solutions provides pre-clinical oncology research services using patient-derived xenograft (PDX) mouse models. They utilize a surgical orthotopic implantation technique to establish PDX models that reliably metastasize and closely mimic human cancer progression. Certis has affiliations with major cancer centers, an expanding tumor bank, and a new pre-clinical facility. Their PDX models have been shown in publications to accurately reflect patient tumor responses to various cancer drugs.
Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENTKanhu Charan
This document provides guidelines for the management of gliomas from the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO). It defines grading criteria for gliomas and provides treatment recommendations based on tumor type, grade, molecular markers and other factors. The recommendations cover initial treatment, adjuvant therapy and options for recurrent gliomas, with an emphasis on radiation therapy, chemotherapy regimens and clinical trial enrollment.
USE OF PET – HEALTH CARE POLICY PERSPECTIVESRuby Med Plus
POSITRON EMISSION TOMOGRAPHY (PET) USE BY TERTIARY HEALTH CARE CENT RES AND ITS ACCESSIBILITY TO POPULATION: A POLICY PERSPECTIVE. a BRIEF Cost-Benefit analysis.
Certis Oncology | Pre-Clinical Research OfferingsArthurHolmes2
Certis Oncology Solutions provides pre-clinical oncology research services using Patient-Derived Orthotopic Xenograft (PDOX) mouse models. They have expanded their facilities and tumor bank. PDOX models more accurately reflect human cancer compared to traditional PDX models by implanting tumors in their original sites. Certis has affiliations with physicians to obtain tumors and drug response data. They have established over 300 PDOX models representing various cancer types. Certis offers drug screening and individualized treatment data to support cancer research and drug development. They have published several studies demonstrating the clinical relevance and predictive power of their PDOX models.
Certis OncologySolutions provides pre-clinical cancer research services using a technique called Patient-Derived Orthotopic Xenograft (PDOX) mouse modeling. They have an expanding tumor bank with over 300 patient tumors and drug response data. Their facilities include a 7,000 square foot facility in San Diego with lab space. Their unique PDOX model implants patient tumor samples into mice in the same anatomical site as the original tumor to provide a more clinically relevant model for testing drug therapies. Recent studies have shown their PDOX models accurately mimic patient responses to therapies. They offer guidance on pre-clinical studies, execution of drug screening, and publishing assistance to support cancer research.
Certis Oncology Solutions provides pre-clinical oncology research services using patient-derived xenograft (PDX) mouse models. They utilize a surgical orthotopic implantation technique to establish PDX models that reliably metastasize and closely mimic human cancer progression. Certis has affiliations with major cancer centers, an expanding tumor bank, and a new pre-clinical facility. Their PDX models have been shown in publications to accurately reflect patient tumor responses to various cancer drugs.
Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENTKanhu Charan
This document provides guidelines for the management of gliomas from the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO). It defines grading criteria for gliomas and provides treatment recommendations based on tumor type, grade, molecular markers and other factors. The recommendations cover initial treatment, adjuvant therapy and options for recurrent gliomas, with an emphasis on radiation therapy, chemotherapy regimens and clinical trial enrollment.
USE OF PET – HEALTH CARE POLICY PERSPECTIVESRuby Med Plus
POSITRON EMISSION TOMOGRAPHY (PET) USE BY TERTIARY HEALTH CARE CENT RES AND ITS ACCESSIBILITY TO POPULATION: A POLICY PERSPECTIVE. a BRIEF Cost-Benefit analysis.
The RAPIDO trial tested a new experimental treatment for locally advanced rectal cancer that involved short-course radiotherapy followed by chemotherapy before surgery, compared to the standard treatment of long-course chemoradiotherapy followed by surgery and then chemotherapy. The results showed that the experimental treatment led to a lower rate of disease-related treatment failures and distant metastases, along with a doubled rate of pathologic complete responses, without increasing toxicities or compromising survival rates. This provides evidence that the experimental approach may be a new standard of care for high-risk locally advanced rectal cancer.
Total neoadjuvant therapy for rectal cancer 2016Mohamed Abdulla
1) Total neoadjuvant therapy, consisting of chemotherapy followed by chemoradiation and surgery, may improve outcomes for rectal cancer over the traditional approach.
2) Ongoing clinical trials are investigating selective use of radiation and whether radiation can be omitted from some neoadjuvant regimens based on risk factors and response.
3) Near total neoadjuvant therapy with upfront chemotherapy alone may achieve pathologic complete responses in a third of patients and warrants further exploration as an alternative to traditional chemoradiation.
Advances in immunotherapy, including checkpoint inhibitors targeting CTLA-4 and PD-1, have significantly improved outcomes for patients with metastatic melanoma. Combination immunotherapy with nivolumab and ipilimumab produces response rates over 60%, compared to around 40% for nivolumab alone and 11% for ipilimumab alone. Many patients receiving the combination immunotherapy continue to respond even after stopping treatment, achieving a state of treatment-free survival. While combination immunotherapy is more toxic than single-agent treatments, the toxicities are often manageable. Ongoing research continues to explore optimizing combination immunotherapy regimens to improve outcomes while reducing toxicity.
This document discusses biopsy principles and abdominal tumors in veterinary medicine. It provides guidelines for obtaining biopsy samples, including using the proper technique to procure enough tissue for an accurate diagnosis without increasing the risk of metastasis. Needle biopsy, incisional biopsy, and excisional biopsy are described as common methods. The role of the pathologist in interpreting biopsy results and potential sources of error are also outlined. For abdominal tumors, the document recommends evaluations like radiographs and ultrasound prior to exploration. It states that solitary masses should be explored for diagnosis and possible treatment, while diffuse disease is rarely helped by surgery alone. Factors like tumor stage, site and grade will impact therapy and prognosis.
1. Radiotherapy targeting only para-aortic nodes is insufficient for testicular seminoma patients with a history of pelvic or scrotal surgery, as the primary lymphatic drainage pattern may have been altered.
2. For these cases, the treatment plan should include ipsilateral iliac and inguinal nodes in classic dog-leg AP-PA fields.
3. Prophylactic irradiation of the contralateral iliac, inguinal, or scrotal region may also be indicated for prior maldescensus testis, inguinal or scrotal violation, or pT3/4 primary tumors.
This document summarizes an application brief about using micro-ultrasound to study cancer angiogenesis. It discusses how micro-ultrasound allows researchers to non-invasively visualize 3D tumor volume, neoangiogenesis, and blood perfusion over time in small animal models. This helps researchers better understand cancer development and anti-angiogenic therapies. VisualSonics' micro-ultrasound systems provide high resolution real-time imaging of tumor growth and vascularity to help reduce the number of animals needed for research.
The panel discussion focused on target delineation in glioma. For low grade gliomas, the GTV includes the surgical cavity while the CTV expands 1 cm from the T2/FLAIR hyperintense area. For high grade gliomas, the GTV is the cavity plus enhancing tumor and the CTV expands 2 cm from the GTV while also including any FLAIR abnormalities. Proper trimming of the CTV is discussed to respect anatomical barriers like the ventricles, falx, optic apparatus, brainstem, and interthalamic area. OAR sparing is also emphasized to reduce treatment toxicity.
1. Resection offers the only chance of cure for pancreatic cancer, but adjuvant therapy after surgery may improve outcomes. Studies have shown benefits from chemoradiation over chemotherapy alone.
2. For borderline resectable or locally advanced unresectable disease, neoadjuvant therapy or chemoradiation may help make initially unresectable tumors operable or improve survival compared to chemotherapy alone.
3. Intensity modulated radiation therapy (IMRT) allows safer dose escalation and better sparing of nearby organs compared to 3D conformal radiation, potentially improving local control and survival. Proper motion management and image guidance are needed to fully realize the benefits of IMRT.
Imaging can be used to evaluate pharmacodynamic endpoints in both preclinical and clinical studies. Preclinically, imaging such as PET can provide quantitative data on endpoints like tumor metabolism without invasive procedures. This can help reduce animal studies. Clinically, imaging biomarkers for conditions like osteoporosis, heart disease, and cancer provide anatomical and functional data on targets, proliferation, and hypoxia. Case studies demonstrate how imaging endpoints like tumor size and blood flow changes can support decision making in drug development from early research through approval. Imaging is positioned to continue advancing drug discovery by identifying new pharmacodynamic biomarkers.
The RAPIDO trial compared short-course radiotherapy followed by chemotherapy and surgery to preoperative chemoradiotherapy, surgery, and optional adjuvant chemotherapy in locally advanced rectal cancer. It found that short-course radiotherapy followed by chemotherapy reduced the risk of disease-related treatment failure at 3 years compared to standard chemoradiotherapy. At 3 years, the probability of distant metastases was 20.0% in the experimental group versus 26.8% in the standard care group. The trial demonstrated that incorporating chemotherapy between short-course radiotherapy and surgery decreased distant metastases and improved outcomes for patients with locally advanced rectal cancer.
Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally ad...Enrique Moreno Gonzalez
Current standard for most of the locally advanced rectal cancers is preoperative chemoradiotherapy, and, variably per institution, postoperative adjuvant chemotherapy. Short-course preoperative radiation with delayed surgery has been shown to induce tumour down-staging in both randomized and observational studies. The concept of neo-adjuvant chemotherapy has been proven successful in gastric cancer, hepatic metastases from colorectal cancer and is currently tested in primary colon cancer.
This document discusses the approach towards re-irradiation of common cancers. It begins by noting that local recurrence after radiation therapy and second primary tumors in irradiated areas are challenges, though re-irradiation can provide durable disease control in some cases. It then discusses key considerations for re-irradiation of head and neck cancers, gliomas, gynecological cancers, bone metastases, and brain metastases. Important factors include the initial radiation dose, interval since prior radiation, intent of re-irradiation, cumulative organ doses, and risk versus benefit. Advanced radiation techniques like IMRT can help minimize toxicity risks from re-irradiation. Careful patient selection and multidisciplinary evaluation are emphasized for meaningful survival benefits from re-
1. A single-center phase 2 trial evaluated surgery for malignant pleural mesothelioma after radiotherapy (SMART) in 102 patients with cT1-3N0M0 disease who received radiotherapy followed by extrapleural pneumonectomy within 1 week.
2. After a median follow-up of 46.8 months, the 5-year cumulative incidence of distant recurrence was 62% with the most common sites being the contralateral chest and peritoneal cavity.
3. The results suggest extrapleural pneumonectomy after radiotherapy can be done with good early and long-term results, however minimizing grade 4 post-operative complications remains technically demanding and may affect long-term
Presentation by Scott Oliver, MD. Presented at the 2018 Eyes on a Cure: Patient & Caregiver Symposium, hosted by the Melanoma Research Foundation's CURE OM initiative.
SOP CONFERENCE PROTOCOLS FOR BEGINNERSKanhu Charan
This document provides guidelines and standard operating procedures for stereotaxy radiosurgery and stereotactic body radiation therapy. It discusses patient selection criteria and protocols, simulation, treatment planning, quality assurance procedures, responsibilities of clinical team members, and patient follow-up. Standardized checklists and protocols are recommended to ensure safety and accuracy in patient localization, treatment planning and delivery for different anatomical sites. Strict quality assurance of equipment, imaging, treatment planning systems and patient-specific validation tests are essential parts of the procedures.
ROSE CASE - SRS/ STEREOTACTIC RADIOTHERAPY FOR MENINGIOAMAKanhu Charan
The document describes a case of stereotactic radiosurgery treatment planning for a 41-year-old female patient with a petroclival meningioma. It details her history, imaging findings showing a 2.2x1.9x2.3cm lesion, pathology confirming a grade 1 transitional meningioma, and prior near total excision. A multidisciplinary tumor board decided on stereotactic radiotherapy. Simulation imaging with MRI and CT was performed and the gross tumor volume, planning target volume, and organs at risk were delineated. A dose of 25Gy in 5 fractions was selected and treatment planning was done to meet coverage and organ at risk constraints.
This document provides an overview of Certis Oncology Solutions, a company that uses patient-derived orthotopic xenograft (PDOX) mouse models to test and select cancer therapies. The summary is as follows:
Certis Oncology uses a technique called PDOX modeling where tiny slices of patients' tumors are implanted into mice to test multiple drug therapies simultaneously. This provides oncologists with precise treatment data to individualize cancer care for patients. Certis offers to immortalize and cryopreserve patients' tumors for future drug testing if initial standard of care therapies fail. The company aims to improve survival rates and quality of life by selecting scientifically proven alternative therapies to standards of care.
This document provides an overview of Certis Oncology Solutions and their precision oncology approach using patient-derived xenograft (PDX) mouse models. Certis aims to improve cancer treatment outcomes by determining the best therapy for each individual patient's tumor through testing multiple drug therapies simultaneously in mice models. Their orthotopic PDX models are able to reliably metastasize and closely mimic a patient's tumor progression and response, providing more accurate and timely treatment recommendations compared to standard of care. Certis offers to establish immortalized tumor banks from patient samples that can be used for ongoing drug testing if initial therapies fail in order to continually improve treatment outcomes.
Certis Oncology Solutions provides precision oncology solutions using patient-derived orthotopic xenograft (PDOX) mouse models to determine the best cancer therapies. Their three-step PDOX process implants patient tumor samples into mice to test multiple drug therapies simultaneously. This provides data to help oncologists individualize treatment for patients. Certis aims to improve outcomes by offering scientifically proven alternatives to standard of care therapies through their clinically relevant PDOX models.
The RAPIDO trial tested a new experimental treatment for locally advanced rectal cancer that involved short-course radiotherapy followed by chemotherapy before surgery, compared to the standard treatment of long-course chemoradiotherapy followed by surgery and then chemotherapy. The results showed that the experimental treatment led to a lower rate of disease-related treatment failures and distant metastases, along with a doubled rate of pathologic complete responses, without increasing toxicities or compromising survival rates. This provides evidence that the experimental approach may be a new standard of care for high-risk locally advanced rectal cancer.
Total neoadjuvant therapy for rectal cancer 2016Mohamed Abdulla
1) Total neoadjuvant therapy, consisting of chemotherapy followed by chemoradiation and surgery, may improve outcomes for rectal cancer over the traditional approach.
2) Ongoing clinical trials are investigating selective use of radiation and whether radiation can be omitted from some neoadjuvant regimens based on risk factors and response.
3) Near total neoadjuvant therapy with upfront chemotherapy alone may achieve pathologic complete responses in a third of patients and warrants further exploration as an alternative to traditional chemoradiation.
Advances in immunotherapy, including checkpoint inhibitors targeting CTLA-4 and PD-1, have significantly improved outcomes for patients with metastatic melanoma. Combination immunotherapy with nivolumab and ipilimumab produces response rates over 60%, compared to around 40% for nivolumab alone and 11% for ipilimumab alone. Many patients receiving the combination immunotherapy continue to respond even after stopping treatment, achieving a state of treatment-free survival. While combination immunotherapy is more toxic than single-agent treatments, the toxicities are often manageable. Ongoing research continues to explore optimizing combination immunotherapy regimens to improve outcomes while reducing toxicity.
This document discusses biopsy principles and abdominal tumors in veterinary medicine. It provides guidelines for obtaining biopsy samples, including using the proper technique to procure enough tissue for an accurate diagnosis without increasing the risk of metastasis. Needle biopsy, incisional biopsy, and excisional biopsy are described as common methods. The role of the pathologist in interpreting biopsy results and potential sources of error are also outlined. For abdominal tumors, the document recommends evaluations like radiographs and ultrasound prior to exploration. It states that solitary masses should be explored for diagnosis and possible treatment, while diffuse disease is rarely helped by surgery alone. Factors like tumor stage, site and grade will impact therapy and prognosis.
1. Radiotherapy targeting only para-aortic nodes is insufficient for testicular seminoma patients with a history of pelvic or scrotal surgery, as the primary lymphatic drainage pattern may have been altered.
2. For these cases, the treatment plan should include ipsilateral iliac and inguinal nodes in classic dog-leg AP-PA fields.
3. Prophylactic irradiation of the contralateral iliac, inguinal, or scrotal region may also be indicated for prior maldescensus testis, inguinal or scrotal violation, or pT3/4 primary tumors.
This document summarizes an application brief about using micro-ultrasound to study cancer angiogenesis. It discusses how micro-ultrasound allows researchers to non-invasively visualize 3D tumor volume, neoangiogenesis, and blood perfusion over time in small animal models. This helps researchers better understand cancer development and anti-angiogenic therapies. VisualSonics' micro-ultrasound systems provide high resolution real-time imaging of tumor growth and vascularity to help reduce the number of animals needed for research.
The panel discussion focused on target delineation in glioma. For low grade gliomas, the GTV includes the surgical cavity while the CTV expands 1 cm from the T2/FLAIR hyperintense area. For high grade gliomas, the GTV is the cavity plus enhancing tumor and the CTV expands 2 cm from the GTV while also including any FLAIR abnormalities. Proper trimming of the CTV is discussed to respect anatomical barriers like the ventricles, falx, optic apparatus, brainstem, and interthalamic area. OAR sparing is also emphasized to reduce treatment toxicity.
1. Resection offers the only chance of cure for pancreatic cancer, but adjuvant therapy after surgery may improve outcomes. Studies have shown benefits from chemoradiation over chemotherapy alone.
2. For borderline resectable or locally advanced unresectable disease, neoadjuvant therapy or chemoradiation may help make initially unresectable tumors operable or improve survival compared to chemotherapy alone.
3. Intensity modulated radiation therapy (IMRT) allows safer dose escalation and better sparing of nearby organs compared to 3D conformal radiation, potentially improving local control and survival. Proper motion management and image guidance are needed to fully realize the benefits of IMRT.
Imaging can be used to evaluate pharmacodynamic endpoints in both preclinical and clinical studies. Preclinically, imaging such as PET can provide quantitative data on endpoints like tumor metabolism without invasive procedures. This can help reduce animal studies. Clinically, imaging biomarkers for conditions like osteoporosis, heart disease, and cancer provide anatomical and functional data on targets, proliferation, and hypoxia. Case studies demonstrate how imaging endpoints like tumor size and blood flow changes can support decision making in drug development from early research through approval. Imaging is positioned to continue advancing drug discovery by identifying new pharmacodynamic biomarkers.
The RAPIDO trial compared short-course radiotherapy followed by chemotherapy and surgery to preoperative chemoradiotherapy, surgery, and optional adjuvant chemotherapy in locally advanced rectal cancer. It found that short-course radiotherapy followed by chemotherapy reduced the risk of disease-related treatment failure at 3 years compared to standard chemoradiotherapy. At 3 years, the probability of distant metastases was 20.0% in the experimental group versus 26.8% in the standard care group. The trial demonstrated that incorporating chemotherapy between short-course radiotherapy and surgery decreased distant metastases and improved outcomes for patients with locally advanced rectal cancer.
Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally ad...Enrique Moreno Gonzalez
Current standard for most of the locally advanced rectal cancers is preoperative chemoradiotherapy, and, variably per institution, postoperative adjuvant chemotherapy. Short-course preoperative radiation with delayed surgery has been shown to induce tumour down-staging in both randomized and observational studies. The concept of neo-adjuvant chemotherapy has been proven successful in gastric cancer, hepatic metastases from colorectal cancer and is currently tested in primary colon cancer.
This document discusses the approach towards re-irradiation of common cancers. It begins by noting that local recurrence after radiation therapy and second primary tumors in irradiated areas are challenges, though re-irradiation can provide durable disease control in some cases. It then discusses key considerations for re-irradiation of head and neck cancers, gliomas, gynecological cancers, bone metastases, and brain metastases. Important factors include the initial radiation dose, interval since prior radiation, intent of re-irradiation, cumulative organ doses, and risk versus benefit. Advanced radiation techniques like IMRT can help minimize toxicity risks from re-irradiation. Careful patient selection and multidisciplinary evaluation are emphasized for meaningful survival benefits from re-
1. A single-center phase 2 trial evaluated surgery for malignant pleural mesothelioma after radiotherapy (SMART) in 102 patients with cT1-3N0M0 disease who received radiotherapy followed by extrapleural pneumonectomy within 1 week.
2. After a median follow-up of 46.8 months, the 5-year cumulative incidence of distant recurrence was 62% with the most common sites being the contralateral chest and peritoneal cavity.
3. The results suggest extrapleural pneumonectomy after radiotherapy can be done with good early and long-term results, however minimizing grade 4 post-operative complications remains technically demanding and may affect long-term
Presentation by Scott Oliver, MD. Presented at the 2018 Eyes on a Cure: Patient & Caregiver Symposium, hosted by the Melanoma Research Foundation's CURE OM initiative.
SOP CONFERENCE PROTOCOLS FOR BEGINNERSKanhu Charan
This document provides guidelines and standard operating procedures for stereotaxy radiosurgery and stereotactic body radiation therapy. It discusses patient selection criteria and protocols, simulation, treatment planning, quality assurance procedures, responsibilities of clinical team members, and patient follow-up. Standardized checklists and protocols are recommended to ensure safety and accuracy in patient localization, treatment planning and delivery for different anatomical sites. Strict quality assurance of equipment, imaging, treatment planning systems and patient-specific validation tests are essential parts of the procedures.
ROSE CASE - SRS/ STEREOTACTIC RADIOTHERAPY FOR MENINGIOAMAKanhu Charan
The document describes a case of stereotactic radiosurgery treatment planning for a 41-year-old female patient with a petroclival meningioma. It details her history, imaging findings showing a 2.2x1.9x2.3cm lesion, pathology confirming a grade 1 transitional meningioma, and prior near total excision. A multidisciplinary tumor board decided on stereotactic radiotherapy. Simulation imaging with MRI and CT was performed and the gross tumor volume, planning target volume, and organs at risk were delineated. A dose of 25Gy in 5 fractions was selected and treatment planning was done to meet coverage and organ at risk constraints.
This document provides an overview of Certis Oncology Solutions, a company that uses patient-derived orthotopic xenograft (PDOX) mouse models to test and select cancer therapies. The summary is as follows:
Certis Oncology uses a technique called PDOX modeling where tiny slices of patients' tumors are implanted into mice to test multiple drug therapies simultaneously. This provides oncologists with precise treatment data to individualize cancer care for patients. Certis offers to immortalize and cryopreserve patients' tumors for future drug testing if initial standard of care therapies fail. The company aims to improve survival rates and quality of life by selecting scientifically proven alternative therapies to standards of care.
This document provides an overview of Certis Oncology Solutions and their precision oncology approach using patient-derived xenograft (PDX) mouse models. Certis aims to improve cancer treatment outcomes by determining the best therapy for each individual patient's tumor through testing multiple drug therapies simultaneously in mice models. Their orthotopic PDX models are able to reliably metastasize and closely mimic a patient's tumor progression and response, providing more accurate and timely treatment recommendations compared to standard of care. Certis offers to establish immortalized tumor banks from patient samples that can be used for ongoing drug testing if initial therapies fail in order to continually improve treatment outcomes.
Certis Oncology Solutions provides precision oncology solutions using patient-derived orthotopic xenograft (PDOX) mouse models to determine the best cancer therapies. Their three-step PDOX process implants patient tumor samples into mice to test multiple drug therapies simultaneously. This provides data to help oncologists individualize treatment for patients. Certis aims to improve outcomes by offering scientifically proven alternatives to standard of care therapies through their clinically relevant PDOX models.
Certis Oncology provides precision oncology solutions through patient-derived tumor xenograft (PDOX) mouse models. Their technique implants small samples of patients' tumors into mice to test potential drug therapies. This identifies effective and ineffective treatments faster than standard methods. It also enables tumor banking for future testing. Certis works with oncologists, patients, and pharmaceutical companies to advance precision cancer care and drug development.
Precision Oncology: Combining Orthotopic-PDX Models and MRI, Moving Research ...Scintica Instrumentation
Certis Oncology Solutions is a precision oncology and translational science company. It works directly with cancer patients and their oncologists to help determine the best therapies for individuals, and also partners with pharmaceutical companies to help develop the next generation of anticancer therapies. Certis’s approach to studying drug efficacy is rooted in orthotopic patient-derived xenograft (O-PDX) models. Because tumors are internal to the animal, they usually cannot be measured by calipers. Certis overcomes this challenge by using magnetic resonance imaging (MRI), employing the Aspect M3 Compact MRI to generate high-resolution 3D anatomical images to monitor anti-cancer therapies in real-time.
Topics that were discussed in this webinar :
- Overview of precision oncology and testing platforms
- Comparison on subcutaneous and orthotopic in vivo models
- Imaging modalities for pre-clinical in vivo studies
- Applications of MRI in precision oncology and preclinical in vivo pharmacology studies
This document discusses bladder-conserving therapy for muscle-invading bladder cancer as an alternative to radical cystectomy. A study of 106 patients found that receiving transurethral resection followed by chemotherapy and radiation resulted in a five-year overall survival rate of 52% and 43% were able to preserve their bladders. For those who received the full radiation and chemotherapy protocol, the five-year freedom from invasive bladder cancer recurrence was 79%. New advances in stereotactic body radiosurgery allow for more precise radiation treatment of the bladder which has high local control rates of 85-90% for bladder cancer.
- The Personalized OncoGenomics (POG) program at the British Columbia Cancer Agency conducted whole-genome analysis on tumors from 100 patients with advanced or incurable cancers to inform treatment decisions.
- Fresh tumor and blood samples were obtained from patients and underwent whole-genome and RNA sequencing. Computational analysis identified potential driver mutations, genes and pathways.
- A multidisciplinary team discussed genomic findings weekly and established guidelines for interpreting and communicating results to integrate them into patient care. Genomic findings were considered actionable in 55 of 78 cases that underwent whole-genome analysis, and motivated treatment changes in 23 cases.
- The experience demonstrated that a multidisciplinary team can implement an approach where whole-genome
DEBATE IN CA BLADDER TMT VS CYSTECTOMYKanhu Charan
1) Dr. KanhuCharanPatro is a radiation oncologist who specializes in stereotactic radiation oncology for treating cancers like urinary bladder cancer.
2) The document discusses trimodal therapy (TMT) versus radical cystectomy (surgery to remove the bladder) for treating urinary bladder cancer, citing evidence from studies that TMT may provide comparable survival outcomes to cystectomy with fewer side effects and better quality of life.
3) A meta-analysis of over 50,000 patients found that TMT had non-inferior overall survival rates to cystectomy at over 10 years and may be a reasonable alternative for patients who cannot undergo or do not want surgery.
Challenges and Opportunities for Digital PCR in the CLIA Laboratory of the Mo...Kate Barlow
Anthony Magliocco, Chair of Anatomical Pathology, Moffitt Cancer Center, USA
The Moffit Cancer Center is one of the largest NCI designated comprehensive free-standing cancer centers in the USA. The center has developed one of the most advanced personalized cancer medicine treatment programs in the world. This program is supported by a comprehensive and advanced CLIA molecular diagnostics. Digital PCR assays are currently being developed for several clinical applications including TKI resistance monitoring in patients with advanced lung cancer. The challenges and opportunities in deploying digital PCR into clinical practice will be discussed.
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
Pharmacology Forever ! has been set as a meeting in recognition of Frits Peters tremendous involvement in pharmacology. This presentation discusses latest drug development methods and is illustrated by exemple of new drugs and target in oncology.
Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...Diaa A. Hameed
This document discusses the evidence for neoadjuvant chemotherapy (NAC) as the standard of care for muscle-invasive bladder cancer (MIBC). It summarizes several key studies that have demonstrated the benefits of NAC, including improved survival rates and decreased risk of death. One study showed a 13% reduction in mortality and 5% improvement in 5-year survival. Later studies provided longer-term data showing ongoing survival benefits up to 10 years later. The document also addresses concerns about NAC delaying surgery or exhausting patients, but cites evidence it does not increase perioperative risks or prevent planned cystectomy. It presents cases from the author's own study demonstrating response rates to NAC. In the end, it questions how
This study evaluated outcomes of 28 patients with intracranial meningiomas treated with hypofractionated radiosurgery. Most tumors were treated with 22.5-30 Gy delivered in 5 fractions. With a mean follow up of 32.6 months, the local tumor control rate was 100% with only one instance of marginal progression. Symptoms improved or resolved in over 66% of patients who originally presented with symptoms. Side effects occurred in 4 patients but the permanent morbidity rate was low at 3.5%. Hypofractionated radiosurgery provided high tumor control with a low risk of side effects, even for large tumors greater than 9 cm3.
APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENTDinie Fariz
Next generation sequencing (NGS) has revolutionized cancer treatment by enabling high throughput DNA sequencing. This document discusses several applications of NGS in cancer treatment including whole exome sequencing of tumors from 25 patients to identify genetic mutations, using avatar mouse models to test proposed treatment strategies, detecting mutations in liquid biopsies, and identifying somatic mutations in leukemia patients. Challenges of NGS include analyzing large amounts of data, accurately interpreting variants, and addressing ethical issues.
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers
Preliminary Study on Monitoring Drug Resistance of Colon Cancer with Intravox...semualkaira
The current study investigated the role of intravoxel incoherent motion-DWI (IVIM-DWI) in evaluating drug
resistance in colon cancer xenografts and explored possible biomarkers.
Similar to Certis Preclinical Slideshare | PDF (20)
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.